Design, synthesis and evaluation of human telomerase inhibitors based upon a tetracyclic structural motif

Anti-Cancer Drug Design

Volumn 14, Issue 4, 1999, Pages 373-382

  Perry, Philip J ^a,b   Gowan, Sharon M ^a   Read, Martin A ^a   Kelland, Lloyd R ^a   Neidle, Stephen ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

Author; Here; Insert; Key; Please; Words

Indexed keywords

3 [2(DIETHYLAMINO)ETHOXY]BENZO[B]NAPHTHO[2,3 D]FURAN 6,11 DIONE; 3 [2(DIMETHYLAMINO)ETHOXY]BENZO[B]NAPHTHO[2,3 D]FURAN 6,11 DIONE; 3 [2(DIMETHYLAMINO)ETHOXY]BENZO[B]NAPHTHO[2,3 D]FURAN 6,11 DIONE METHIODIDE; 3 HYDROXYBENZO[B]NAPHTHO[2,3 D]FURAN 6,11 DIONE; 9 HYDROXYELLIPTICINE; ENZYME INHIBITOR; TELOMERASE; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL FREE SYSTEM; CHROMATOPHORE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

AMINO ACID MOTIFS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; TAQ POLYMERASE; TELOMERASE;

EID: 0032697230     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Allsopp R.C., Harley C.B. (1995) Evidence for a critical telomere length in senescent human fibroblasts. Experimental Cell Research, 219, 130.
2. Blackburn E.H. (1991) Structure and function of telomeres. Nature, 350, 569.
3. Blackburn E.H. (1994) Telomeres: no end in sight. Cell, 77, 621.
4. Blasco M.A., Lee H.-W., Hande M.P., Samper E., Lansdorp P.M., Depinho R.A., Greider C.W. (1997) Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell, 91, 25.
5. Bodnar A.G., Ouellette M., Frolkis M., Holt S.E., Chiu C.P., Morin G.B., Harley C.B., Shay J.W., Lichtsteiner S., Wright W.E. (1998) Extension of life-span by introduction of telomerase into normal human cells. Science, 279, 349.
6. Cheng C.C., Dong Q., Liu D.-F., Luo Y-L., Liu L.F., Chen A.Y., Yu C., Savaraj N., Chou T.-C. (1993) Design of antineoplastic agents on the basis of the '2-phenylnaphthalene-type' structural pattern. 2. Synthesis and biological activity studies of benzo[b]naphtho[2,3-d]furan-6,11-dione derivatives. Journal of Medicinal Chemistry, 36, 4108.
7. Counter C.M., Hahn W.C., Wei W, Caddle S.D., Beijersbergen R.L., Lansdorp P.M., Sedivy J.M., Weinberg R.A. (1998) Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proceedings of the National Academy of Sciences, USA, 95, 14723.
8. Feng J., Funk W., Wang S.-S., Weinrich S.L., Avilion A.A., Chiu C.-P., Adams R.R., Chang E., Allsopp R.C., Yu J., Le S., West M.D., Harley C.B., Andrews W.H., Greider C.W., Villeponteau B. (1995) The RNA component of human telomerase. Science, 269, 1236.
9. Fletcher T.M., Sun D., Salazar M., Hurley L.H. (1998) Effect of DNA secondary structure on human telomerase activity. Biochemistry, 37, 5536.
10. Hamilton S.E., Corey D.R. (1996) Telomerase: anti-cancer target or just a fascinating enzyme? Chemistry & Biology, 3, 863.
11. Harley C.B., Futcher A.B., Greider C.W. (1990) Telomeres shorten during ageing of human fibroblasts. Nature, 345, 458.
12. Kelland L.R., Abel G., McKeage M.J., Jones M., Goddard P.M., Valenti M., Murrer B.A., Harrap K.R. (1993) Preclinical antitumor evaluation of bis-acetato-aminedichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Research, 53, 2581.
13. Kelland L.R., Gowan S.M., Harrison R.J., Wood A.A., Read M.A., Dosanjh H.S., Perry P.J., Reszka A.P., Davies R.T., Neidle S. (1999) Bisubstituted tricyclic chromophores as small molecule inhibitors of human telomerase: biological and modelling studies. Proceedings of the American Association for Cancer Research, 40, 1996 (meeting abstract).
14. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L.C., Coviello G.M., Wright WE., Weinrich R.L., Shay J.W. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science, 266, 2011.
15. Kruk P.A., Rampino N.J., Bohr V.A. (1995) DNA damage and repair in telomeres: relation to aging. Proceedings of the National Academy of Sciences, USA, 92, 258.
16. Ku W.-C., Cheng A.-J., Wang T.-C.V. (1997) Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture. Biochemical and Biophysical Research Communications, 241, 730.
17. Lee H.-W., Blasco M.A., Gottlieb G.J., Horner J.W., Greider C.W., Depinho R.A. (1998) Essential role of mouse telomerase in highly proliferative organs. Nature, 392, 569.
18. Luty B.A., Wasserman Z.R., Stouten P.F.W., Hodge C.N., Zacharias M., McCammon J.A. (1995) A molecular mechanics/grid method for evaluation of ligand-receptor interactions. Journal of Computational Chemistry, 16, 454.
19. n among vertebrates. Proceedings of the National Academy of Sciences, USA, 86, 7049.
20. Mohamadi F., Richards N.G.J., Guida W.C., Liskamp R., Lipton M., Caufield C., Chang G., Hendrickson T., Still W.C. (1990) Macromodel - an integrated software system for modeling organic bioorganic molecules using molecular mechanics. Journal of Computational Chemistry, 11, 440.
21. Morin G.B. (1989) The human telomere terminal transferase activity is a ribonucleoprotein that synthesises TTAGGG repeats. Cell, 59, 521.
22. Niida H., Matsumoto T., Satoh H., Shiwa M., Tokutake Y., Furuichi Y., Shinkai Y. (1998) Severe growth defect in mouse cells lacking the telomerase RNA component. Nature Genetics, 19, 203.
23. Perry P.J., Kelland L.R. (1998) Telomeres and telomerase: targets for cancer chemotherapy? Expert Opinion on Therapeutic Patents, 8, 1567.
24. Perry P.J., Gowan S.M., Reszka A.P., Polucci P., Jenkins T.C., Kelland L.R., Neidle S. (1998a) 1,4-and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase. Journal of Medicinal Chemistry, 41, 3253.
25. Perry P.J., Reszka A.P., Wood A.A., Read M.A., Gowan S.M., Dosanjh H.S., Trent J.O., Jenkins T.C., Kelland L.R., Neidle S. (1998b) Human telomerase inhibition by regioisomeric disubstituted amidoanthracene-9,10-diones. Journal of Medicinal Chemistry, 41, 4873.
26. Perry P.J., Read M.A., Davies R.T., Gowan S.M., Reszka A.P., Wood A.A., Kelland L.R., Neidle S. (1999) 2,7-Disubstituted amidofluorenone derivatives as inhibitors of human telomerase. Journal of Medicinal Chemistry, 42, 2679.
27. Pitts A.E., Corey D.R. (1999) The telomerase challenge - an unusual problem in drug discovery. Drug Discovery Today, 4, 155.
28. Raymond E., Sun D., Chen S.-F., Windle B., von Hoff D.D. (1996) Agents that target telomerase and telomeres. Current Opinion in Biotechnology, 1, 583.
29. Sato N., Mizumoto K., Kusumoto M., Niiyama H., Maehara N., Ogawa T., Tanaka M. (1998) 9-Hydroxyellipticine inhibits telomerase activity in human pancreatic cancer cells. FEBS Letters, 441, 318.
30. Sharma S., Raymond E., Soda H., Sun D., Hilsenbeck S.G., Sharma A., Izbicka E., Windle B., von Hoff D.D. (1997) Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Annals of Oncology, 8, 1063.
31. 3] G-tetraplex. Structure, 1, 263.
32. Zahler A.M., Williamson J.R., Cech T.R., Prescott D.M. (1991) Inhibition of telomerase by G-quartet DNA structures. Nature, 350, 718.
33. Zhu J., Wang H., Bishop J.M., Blackburn E.H. (1999) Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening. Proceedings of the National Academy of Sciences, USA, 96, 3723.